FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washi

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ngton, D.C. 20549	OMB APPROVAL

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Horton Kenneth L						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								Check	all app Dired	olicable)		Ssuer Owner (specify
(Last)	TEV DU	3. [Date of Earliest Transaction (Month/Day/Year)								X	below)		below) Legal Officer				
C/O VERTEX PHARMACEUTICALS INCORPORATED					12/	12/12/2013												
130 WAVERLY ST.					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)														X Form filed by One Reporting Person				
CAMBRIDGE MA 02139													Form filed by More than One Reporting Person					
(City)	(State)	(Zip)															
		Tal	ole I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefici	ially C	Owne	ed		
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N					Execution Date,		ate,				Acquired (A) or (D) (Instr. 3, 4 an		d 5) Secur Benef		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(1113411 4)
Common Stock 12/12/20					013	13		S ⁽¹⁾		4,532	D	\$65.46	65.46 ⁽²⁾⁽³⁾		6,624	D		
Common Stock															366	I	401(k)	
		7	able II								osed of, convertib				ned			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security) if any	emed tion Date, n/Day/Year)	4. Transa Code (8)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$65.46 (range \$65.05 to \$65.91).
- 3. Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(D)

Remarks:

Kenneth L. Horton 12/12/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.